Enzo Biochem, Inc.
ENZB · OTC
4/30/2025 | 1/31/2025 | 10/31/2024 | 7/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.03 | 0.09 | 0.06 | -0.00 |
| FCF Yield | -14.34% | -6.61% | -15.71% | -2.03% |
| EV / EBITDA | 2.78 | 4.26 | -5.41 | 22.38 |
| Quality | ||||
| ROIC | -7.14% | -3.85% | -6.40% | -4.31% |
| Gross Margin | 38.80% | 51.61% | 40.75% | 42.79% |
| Cash Conversion Ratio | 1.15 | 1.32 | 2.66 | 0.08 |
| Growth | ||||
| Revenue 3-Year CAGR | -27.13% | -28.95% | -32.56% | -33.21% |
| Free Cash Flow Growth | -72.04% | 77.79% | -681.29% | 59.80% |
| Safety | ||||
| Net Debt / EBITDA | 10.97 | 28.94 | 15.71 | -102.22 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | -13.53 |
| Efficiency | ||||
| Inventory Turnover | 0.69 | 0.59 | 0.58 | 0.63 |
| Cash Conversion Cycle | 159.79 | 186.88 | 180.89 | 161.73 |